Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.

about

Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.A Pyrazolo[3,4-d]pyrimidine Compound Reduces Cell Viability and Induces Apoptosis in Different Hematological Malignancies.

P2860

Q39200835-E916E0FB-B5FE-4739-B82E-A814A25CCD62 Q41811693-17DCBCE0-1D50-45DA-80ED-F43960AB9E4C

P2860

Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.

Item

http://www.wikidata.org/entity/Q38544216

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pharmacodynamic considerations ...... l malignancies in the elderly.

@en

type

Item

label

Pharmacodynamic considerations ...... l malignancies in the elderly.

@en

prefLabel

Pharmacodynamic considerations ...... l malignancies in the elderly.

@en

P1476

Pharmacodynamic considerations ...... l malignancies in the elderly.

@en

P2093

Anna Korycka-Wołowiec

http://www.w3.org/2001/XMLSchema#string

Dariusz Wołowiec

http://www.w3.org/2001/XMLSchema#string

Tadeusz Robak

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

New strategies in chronic lymphocytic leukemia: shifting treatment paradigms

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

P304

1371-1391

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2015.1055246

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26156752

http://www.w3.org/2001/XMLSchema#string

Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.

about

P2860

P2860

Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698